Frank Marinkovich, MD
Internal Medicine · Kirkland, WANPI 1407867690
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Novo Nordisk at 27.5% of the total. Reporting peaked in 2023 at $226 and has fallen 62.4% since, to $85 in 2024.
Across 32 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$173
- Lilly USA, LLC$165
- Halozyme Inc$78
- Amgen$66
- Takeda Pharmaceuticals U.S.A., Inc.$37
- Johnson & Johnson$32
- plus $79 from 4 others
What the payments were for
- Food & beverage$629100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $173 |
| Lilly USA, LLC | 8 | $165 |
| Halozyme Inc | 4 | $78 |
| Amgen(2 entities) | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $37 |
| Johnson & Johnson | 1 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Si-bone, Inc. | 1 | $23 |
| Boston Scientific | 1 | $17 |
| Pajunk Medical Systems, LP | 1 | $14 |
How this compares
$629 in reported general payments places this provider in the 85th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $17,016 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,975 |
| Levothyroxine Sodium | 104 | $1,154 |
| Rosuvastatin Calcium | 87 | $954 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $948 |
| Testosterone Cypionate | 14 | $804 |
| Tamsulosin Hcl | 56 | $692 |
| Atorvastatin Calcium | 71 | $686 |
| Ezetimibe | 36 | $657 |
| Omeprazole | 41 | $650 |
| Pantoprazole Sodium | 37 | $626 |
| Metoprolol Succinate | 41 | $561 |
| Doxazosin Mesylate | 31 | $544 |
| Losartan Potassium | 65 | $492 |
| Amlodipine Besylate | 66 | $471 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Kirkland
- Peter ShalitSeattle$1M
- Lawrence LoebBellevue$784K
- Shawna PurcellOlympia$294K
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Alan KellySpokane Valley$96K
- Emily EgdaminWenatchee$81K
- Royce MorrisonTacoma$72K
- Safoora ZakaPort Orchard$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.